DOCSLIB.ORG

Pancancer IO360 Human Vapril2018

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text

Load more

Gene Name Official Full Gene name Alias/Prev Symbols Previous Name(s) Alias Symbol(s) Alias Name(s) A2M alpha-2-macroglobulin FWP007,S863-7,CPAMD5 ABCF1 ATP binding cassette subfamily F member 1 ABC50 ATP-binding cassette, sub-family F (GCN20),EST123147 member 1 ACVR1C activin A receptor type 1C activin A receptor, type IC ALK7,ACVRLK7 ADAM12 ADAM metallopeptidase domain 12 a disintegrin and metalloproteinase domainMCMPMltna,MLTN 12 (meltrin alpha) meltrin alpha ADGRE1 adhesion G protein-coupled receptor E1 TM7LN3,EMR1 egf-like module containing, mucin-like, hormone receptor-like sequence 1,egf-like module containing, mucin-like, hormone receptor-like 1 ADM adrenomedullin AM ADORA2A adenosine A2a receptor ADORA2 RDC8 AKT1 AKT serine/threonine kinase 1 v-akt murine thymoma viral oncogene homologRAC,PKB,PRKBA,AKT 1 ALDOA aldolase, fructose-bisphosphate A aldolase A, fructose-bisphosphate ALDOC aldolase, fructose-bisphosphate C aldolase C, fructose-bisphosphate ANGPT1 angiopoietin 1 KIAA0003,Ang1 ANGPT2 angiopoietin 2 Ang2 ANGPTL4 angiopoietin like 4 angiopoietin-like 4 pp1158,PGAR,ARP4,HFARP,FIAF,NL2fasting-induced adipose factor,hepatic angiopoietin-related protein,PPARG angiopoietin related protein,hepatic fibrinogen/angiopoietin-related protein,peroxisome proliferator-activated receptor (PPAR) gamma induced angiopoietin-related protein,angiopoietin-related protein 4 ANLN anillin actin binding protein anillin (Drosophila Scraps homolog), actin bindingANILLIN,Scraps,scra protein,anillin, actin binding protein (scraps homolog, Drosophila) APC APC, WNT signaling pathway regulator adenomatosis polyposis coli,adenomatous polyposisDP2,DP3,DP2.5,PPP1R46 coli protein phosphatase 1, regulatory subunit 46 APH1B aph-1 homolog B, gamma-secretase subunit anterior pharynx defective 1 homolog B (C. PSFL,APH-1B,DKFZp564D0372elegans),APH1B gamma secretase subunit API5 apoptosis inhibitor 5 AAC-11,API5L1,AAC11 API5-like 1,fibroblast growth factor 2-interacting factor 2,migration-inducing protein MIG8 APLNR apelin receptor AGTRL1 angiotensin II receptor-like 1 FLJ90771,APJ,APJR APJ (apelin) receptor APOE apolipoprotein E AD2 Alzheimer disease 2 (APOE*E4-associated, late onset) APOL6 apolipoprotein L6 APOL-VI,APOLVI AQP9 aquaporin 9 SSC1,HsT17287 AREG amphiregulin SDGF,AREGB schwannoma-derived growth factor,amphiregulin B ARG1 arginase 1 arginase, liver ARG2 arginase 2 arginase, type II ARID1A AT-rich interaction domain 1A C1orf4,SMARCF1 SWI/SNF related, matrix associated, actin dependentB120,P270,C10rf4,BAF250,BAF250a regulator of chromatin, subfamily f, member 1,AT rich interactive domain 1A (SWI- like),AT rich interactive domain 1A (SWI-like) ARNT2 aryl hydrocarbon receptor nuclear translocator 2 KIAA0307,bHLHe1 ATF3 activating transcription factor 3 ATM ATM serine/threonine kinase ATA,ATDC,ATC,ATD ataxia telangiectasia mutated (includes complementationTEL1,TELO1 groups A, C and D),ataxiaTEL1, telomere telangiectasia maintenance mutated 1, homolog (S. cerevisiae) AXIN1 axin 1 PPP1R49 protein phosphatase 1, regulatory subunit 49 AXL AXL receptor tyrosine kinase UFO,JTK11,Tyro7,ARK B2M beta-2-microglobulin BAD BCL2 associated agonist of cell death BCL2L8,BBC2 BAMBI BMP and activin membrane bound inhibitor BMP and activin membrane-bound inhibitor NMAhomolog (Xenopus laevis) BATF3 basic leucine zipper ATF-like transcription factor 3 basic leucine zipper transcription factor, ATF-likeJUNDM1,SNFT,JDP1 3 Jun dimerization protein 1 BAX BCL2 associated X, apoptosis regulator BCL2-associated X protein,BCL2 associated BCL2L4X protein BBC3 BCL2 binding component 3 JFY1,PUMA p53-upregulated modulator of apoptosis BBS1 Bardet-Biedl syndrome 1 FLJ23590 BCAT1 branched chain amino acid transaminase 1 BCT1 branched chain aminotransferase 1, cytosolic BCL2 BCL2, apoptosis regulator B-cell CLL/lymphoma 2 Bcl-2,PPP1R50 protein phosphatase 1, regulatory subunit 50 BCL2L1 BCL2 like 1 BCLX,BCL2L,Bcl-X,bcl-xL,bcl-xS,PPP1R52protein phosphatase 1, regulatory subunit 52 BCL6B B-cell CLL/lymphoma 6B ZNF62 zinc finger protein 62,B-cell CLL/lymphomaZBTB28,BAZF 6, member B (zinc finger protein),B-cell CLL/lymphoma 6, member B BID BH3 interacting domain death agonist BIRC3 baculoviral IAP repeat containing 3 API2 baculoviral IAP repeat-containing 3 cIAP2,hiap-1,MIHC,RNF49,MALT2,c-IAP2apoptosis inhibitor 2,TNFR2-TRAF signaling complex protein,mammalian IAP homolog C,inhibitor of apoptosis protein 1 BIRC5 baculoviral IAP repeat containing 5 API4 apoptosis inhibitor 4,baculoviral IAP repeat-containingEPR-1,survivin 5 survivin variant 3 alpha BLK BLK proto-oncogene, Src family tyrosine kinase B lymphoid tyrosine kinase MGC10442 BLM Bloom syndrome RecQ like helicase Bloom syndrome BS,RECQL3,RECQ2 BMP2 bone morphogenetic protein 2 BMP2A BNIP3 BCL2 interacting protein 3 BCL2/adenovirus E1B 19kDa interacting proteinNip3 3 BNIP3L BCL2 interacting protein 3 like BCL2/adenovirus E1B 19kDa interacting proteinNix,BNIP3a 3 like NIP‐3‐like protein X BRCA1 BRCA1, DNA repair associated breast cancer 1, early onset,breast cancer 1RNF53,BRCC1,PPP1R53,FANCS BRCA1/BRCA2-containing complex, subunit 1,protein phosphatase 1, regulatory subunit 53,Fanconi anemia, complementation group S BRCA2 BRCA2, DNA repair associated FANCD1,FACD,FANCD Fanconi anemia, complementation group D1,breastFAD,FAD1,BRCC2,XRCC11 cancer 2, early onset,breastBRCA1/BRCA2-containing cancer 2 complex, subunit 2 BRD3 bromodomain containing 3 bromodomain-containing 3 RING3L,ORFX,KIAA0043 RING3-like BRD4 bromodomain containing 4 bromodomain-containing 4 HUNKI,MCAP,CAP,HUNK1 chromosome-associated protein BRIP1 BRCA1 interacting protein C-terminal helicase 1 OF,BACH1,FANCJ BRCA1/BRCA2-associated helicase 1 BTLA B and T lymphocyte associated BTLA1,CD272 C1QA complement C1q A chain complement component 1, q subcomponent, alpha polypeptide,complement component 1, q subcomponent, A chain,complement C1q chain A C1QB complement C1q B chain complement component 1, q subcomponent, beta polypeptide,complement component 1, q subcomponent, B chain,complement C1q chain B C2 complement C2 complement component 2 C5 complement C5 complement component 5 CPAMD4,C5a,C5b prepro-C5,C5a anaphylatoxin C5AR1 complement C5a receptor 1 C5R1 complement component 5 receptor 1 (C5a ligand),complementC5A,C5AR,CD88 component 5a receptor 1 C7 complement C7 complement component 7 CASP1 caspase 1 IL1BC caspase 1, apoptosis-related cysteine proteaseICE (interleukin 1, beta, convertase),caspasecaspase-1,interleukin 1, apoptosis-related 1, beta, convertase cysteine peptidase (interleukin 1, beta, convertase),caspase 1, apoptosis-related cysteine peptidase CASP3 caspase 3 caspase 3, apoptosis-related cysteine protease,caspaseCPP32,CPP32B,Yama,apopain 3, apoptosis-related cysteine peptidase CASP8 caspase 8 caspase 8, apoptosis-related cysteine protease,caspaseMCH5,MACH,FLICE,Casp-8 8, apoptosis-related cysteine peptidase CASP9 caspase 9 caspase 9, apoptosis-related cysteine protease,caspaseMCH6,ICE-LAP6,APAF-3,PPP1R56 9, apoptosis-related cysteineprotein phosphatasepeptidase 1, regulatory subunit 56 CBLC Cbl proto-oncogene C Cas-Br-M (murine) ectropic retroviral transformingCBL-3,CBL-SL,RNF57 sequence c,Cas-Br-M (murine) ecotropic retroviral transforming sequence c,Cbl proto-oncogene C, E3 ubiquitin protein ligase CCL13 C-C motif chemokine ligand 13 SCYA13 small inducible cytokine subfamily A (Cys-Cys),MCP-4,NCC-1,SCYL1,CKb10,MGC17134 member 13,chemokine (C-C motif) ligand 13 CCL14 C-C motif chemokine ligand 14 SCYA14 small inducible cytokine subfamily A (Cys-Cys),HCC-1,HCC-3,NCC-2,SCYL2,CKb1,MCIF member 14,chemokine (C-C motif) ligand 14 CCL18 C-C motif chemokine ligand 18 SCYA18 small inducible cytokine subfamily A (Cys-Cys),DC-CK1,PARC,AMAC-1,DCCK1,MIP-4,CKb7 member 18, pulmonary and activation-regulated,chemokinepulmonary and activation-regulated (C-C motif) ligand 18 (pulmonary and activation-regulated),chemokine (C-C motif) ligand 18 CCL19 C-C motif chemokine ligand 19 SCYA19 small inducible cytokine subfamily A (Cys-Cys),ELC,MIP-3b,exodus-3,CKb11 member 19,chemokine (C-C motif)CC chemokine ligand 19 ligand 19,macrophage inflammatory protein 3-beta,beta chemokine exodus-3,CK beta-11,EBI1-ligand chemokine CCL2 C-C motif chemokine ligand 2 SCYA2 small inducible cytokine A2 (monocyte chemotacticMCP1,MCP-1,MCAF,SMC-CF,GDCF-2,HC11,MGC9434 protein 1, homologous to monocytemouse Sig-je),chemokine chemotactic protein (C-C motif)1, homologous ligand 2 to mouse Sig-je,monocyte chemoattractant protein-1,monocyte chemotactic and activating factor,monocyte secretory protein JE,small inducible cytokine subfamily A (Cys-Cys), member 2 CCL20 C-C motif chemokine ligand 20 SCYA20 small inducible cytokine subfamily A (Cys-Cys),LARC,MIP-3a,exodus-1,ST38,CKb4 member 20,chemokine (C-C motif) ligand 20 CCL21 C-C motif chemokine ligand 21 SCYA21 small inducible cytokine subfamily A (Cys-Cys),SLC,exodus-2,TCA4,CKb9,6Ckine,ECL member 21,chemokine (C-C motif)beta chemokineligand 21 exodus-2,secondary lymphoid tissue chemokine,Efficient Chemoattractant for Lymphocytes CCL22 C-C motif chemokine ligand 22 SCYA22 small inducible cytokine subfamily A (Cys-Cys),MDC,STCP-1,ABCD-1,DC/B-CK,A-152E5.1,MGC34554 member 22,chemokine (C-C motif) ligand 22 CCL3 C-C motif chemokine ligand 3 SCYA3 small inducible cytokine A3 (homologous to G0S19-1,LD78ALPHA,MIP-1-alphamouse Mip-1a),chemokine (C-C motif) ligand 3 CCL3L1 C-C motif chemokine ligand 3 like 1 D17S1718,SCYA3L,SCYA3L1 small inducible cytokine A3-like 1,chemokineG0S19-2,LD78BETA (C-C motif) ligand 3-like 1 CCL4 C-C motif chemokine
Recommended publications
  • Immuno-Oncology Panel 1

    Immuno-Oncology Panel 1

    Immuno-Oncology panel 1 Gene Symbol Target protein name UniProt ID (& link) Modification* (56 analytes) ADA17 ADAM17 metalloprotease domain 17 P78536 *blanks mean the assay detects the ANXA1 Annexin A1 P04083 non-modified peptide sequence ANXA1 Annexin A1 P04083 ARG2 arginase, type II P78540 ATM Serine-protein kinase ATM, Ataxia telangiectasia mutated Q13315 pS2996 ATM Serine-protein kinase ATM, Ataxia telangiectasia mutated Q13315 ATM Serine-protein kinase ATM, Ataxia telangiectasia mutated Q13315 pS367 ATM Serine-protein kinase ATM, Ataxia telangiectasia mutated Q13315 C10orf54 / VISTA chromosome 10 open reading frame 54 Q9H7M9 CCL5 C-C motif chemokine ligand 5 P13501 CD14 CD14 molecule P08571 CD163 CD163 molecule Q86VB7 CD274 / PDL1 Programmed cell death 1 ligand 1 CD274 Q9NZQ7 CD33 CD33 molecule P20138 CD40/TNR5 tumor necrosis factor receptor superfamily member 5 P25942 CD40/TNR5 tumor necrosis factor receptor superfamily member 5 P25942 CD47 CD47 molecule Q08722 CD70 CD70 antigen P32970 CD74/HG2A CD74 molecule, major histocompatibility complex, class II invariant chain Q8SNA0 CEACAM8 carcinoembryonic antigen-related cell adhesion molecule 8 P31997 CX3CL1 C-X3-C motif chemokine ligand 1 P78423 CXCL10 C-X-C motif chemokine ligand 10 P02778 CXCL13 chemokine (C-X-C motif) ligand 13 O43927 ENTPD1 ectonucleoside triphosphate diphosphohydrolase 1 Q86VV3 FAS/TNR6 Fas (TNF receptor superfamily, member 6) P25445 pY291 FAS/TNR6 Fas (TNF receptor superfamily, member 6) P25445 GAPDH Glyceraldehyde-3-phosphate dehydrogenase P04406 HAVCR2 hepatitis
  • Receptor-Mediated Dimerization of JAK2 FERM Domains Is Required for JAK2 Activation Ryan D Ferrao, Heidi JA Wallweber, Patrick J Lupardus*

    Receptor-Mediated Dimerization of JAK2 FERM Domains Is Required for JAK2 Activation Ryan D Ferrao, Heidi JA Wallweber, Patrick J Lupardus*

    RESEARCH ARTICLE Receptor-mediated dimerization of JAK2 FERM domains is required for JAK2 activation Ryan D Ferrao, Heidi JA Wallweber, Patrick J Lupardus* Department of Structural Biology, Genentech, Inc., South San Francisco, United States Abstract Cytokines and interferons initiate intracellular signaling via receptor dimerization and activation of Janus kinases (JAKs). How JAKs structurally respond to changes in receptor conformation induced by ligand binding is not known. Here, we present two crystal structures of the human JAK2 FERM and SH2 domains bound to Leptin receptor (LEPR) and Erythropoietin receptor (EPOR), which identify a novel dimeric conformation for JAK2. This 2:2 JAK2/receptor dimer, observed in both structures, identifies a previously uncharacterized receptor interaction essential to dimer formation that is mediated by a membrane-proximal peptide motif called the ‘switch’ region. Mutation of the receptor switch region disrupts STAT phosphorylation but does not affect JAK2 binding, indicating that receptor-mediated formation of the JAK2 FERM dimer is required for kinase activation. These data uncover the structural and molecular basis for how a cytokine-bound active receptor dimer brings together two JAK2 molecules to stimulate JAK2 kinase activity. DOI: https://doi.org/10.7554/eLife.38089.001 Introduction Janus kinases (JAKs) are a family of multi-domain non-receptor tyrosine kinases responsible for pleio- tropic regulatory effects on growth, development, immune and hematopoietic signaling (Leonard and O’Shea, 1998). The JAK family consists of four conserved members, including JAK1, *For correspondence: [email protected] JAK2, JAK3, and TYK2, which are differentially activated in response to cytokine and interferon stim- ulation. JAKs are constitutively bound to the intracellular domains of their cognate cytokine signaling Competing interest: See receptors, and are activated after cytokine-mediated dimerization or rearrangement of these recep- page 18 tors establishes a productive receptor signaling complex (Haan et al., 2006).
  • Mast Cells Promote Seasonal White Adipose Beiging in Humans

    Mast Cells Promote Seasonal White Adipose Beiging in Humans

    Diabetes Volume 66, May 2017 1237 Mast Cells Promote Seasonal White Adipose Beiging in Humans Brian S. Finlin,1 Beibei Zhu,1 Amy L. Confides,2 Philip M. Westgate,3 Brianna D. Harfmann,1 Esther E. Dupont-Versteegden,2 and Philip A. Kern1 Diabetes 2017;66:1237–1246 | DOI: 10.2337/db16-1057 Human subcutaneous (SC) white adipose tissue (WAT) localized to the neck and thorax of humans (4–8), and in a increases the expression of beige adipocyte genes in the process known as beiging (9), UCP1-positive adipocytes winter. Studies in rodents suggest that a number of form in subcutaneous (SC) white adipose tissue (WAT) immune mediators are important in the beiging response. (10). Beige adipocytes have unique developmental origins, We studied the seasonal beiging response in SC WAT gene signatures, and functional properties, including being from lean humans. We measured the gene expression of highly inducible to increase UCP1 in response to catechol- various immune cell markers and performed multivariate amines (9,11–13). Although questions exist about whether analysis of the gene expression data to identify genes beige fat can make a meaningful contribution to energy OBESITY STUDIES that predict UCP1. Interleukin (IL)-4 and, unexpectedly, expenditure in humans (reviewed in Porter et al. [14]), the mast cell marker CPA3 predicted UCP1 gene expres- the induction of beige fat in rodent models is associated sion. Therefore, we investigated the effects of mast with increased energy expenditure and improved glucose cells on UCP1 induction by adipocytes. TIB64 mast cells homeostasis (13). responded to cold by releasing histamine and IL-4, and this medium stimulated UCP1 expression and lipolysis by Activation of the sympathetic nervous system by cold 3T3-L1 adipocytes.
  • A Computational Approach for Defining a Signature of Β-Cell Golgi Stress in Diabetes Mellitus

    A Computational Approach for Defining a Signature of Β-Cell Golgi Stress in Diabetes Mellitus

    Page 1 of 781 Diabetes A Computational Approach for Defining a Signature of β-Cell Golgi Stress in Diabetes Mellitus Robert N. Bone1,6,7, Olufunmilola Oyebamiji2, Sayali Talware2, Sharmila Selvaraj2, Preethi Krishnan3,6, Farooq Syed1,6,7, Huanmei Wu2, Carmella Evans-Molina 1,3,4,5,6,7,8* Departments of 1Pediatrics, 3Medicine, 4Anatomy, Cell Biology & Physiology, 5Biochemistry & Molecular Biology, the 6Center for Diabetes & Metabolic Diseases, and the 7Herman B. Wells Center for Pediatric Research, Indiana University School of Medicine, Indianapolis, IN 46202; 2Department of BioHealth Informatics, Indiana University-Purdue University Indianapolis, Indianapolis, IN, 46202; 8Roudebush VA Medical Center, Indianapolis, IN 46202. *Corresponding Author(s): Carmella Evans-Molina, MD, PhD ([email protected]) Indiana University School of Medicine, 635 Barnhill Drive, MS 2031A, Indianapolis, IN 46202, Telephone: (317) 274-4145, Fax (317) 274-4107 Running Title: Golgi Stress Response in Diabetes Word Count: 4358 Number of Figures: 6 Keywords: Golgi apparatus stress, Islets, β cell, Type 1 diabetes, Type 2 diabetes 1 Diabetes Publish Ahead of Print, published online August 20, 2020 Diabetes Page 2 of 781 ABSTRACT The Golgi apparatus (GA) is an important site of insulin processing and granule maturation, but whether GA organelle dysfunction and GA stress are present in the diabetic β-cell has not been tested. We utilized an informatics-based approach to develop a transcriptional signature of β-cell GA stress using existing RNA sequencing and microarray datasets generated using human islets from donors with diabetes and islets where type 1(T1D) and type 2 diabetes (T2D) had been modeled ex vivo. To narrow our results to GA-specific genes, we applied a filter set of 1,030 genes accepted as GA associated.
  • Supplementary Table 1: Adhesion Genes Data Set

    Supplementary Table 1: Adhesion Genes Data Set

    Supplementary Table 1: Adhesion genes data set PROBE Entrez Gene ID Celera Gene ID Gene_Symbol Gene_Name 160832 1 hCG201364.3 A1BG alpha-1-B glycoprotein 223658 1 hCG201364.3 A1BG alpha-1-B glycoprotein 212988 102 hCG40040.3 ADAM10 ADAM metallopeptidase domain 10 133411 4185 hCG28232.2 ADAM11 ADAM metallopeptidase domain 11 110695 8038 hCG40937.4 ADAM12 ADAM metallopeptidase domain 12 (meltrin alpha) 195222 8038 hCG40937.4 ADAM12 ADAM metallopeptidase domain 12 (meltrin alpha) 165344 8751 hCG20021.3 ADAM15 ADAM metallopeptidase domain 15 (metargidin) 189065 6868 null ADAM17 ADAM metallopeptidase domain 17 (tumor necrosis factor, alpha, converting enzyme) 108119 8728 hCG15398.4 ADAM19 ADAM metallopeptidase domain 19 (meltrin beta) 117763 8748 hCG20675.3 ADAM20 ADAM metallopeptidase domain 20 126448 8747 hCG1785634.2 ADAM21 ADAM metallopeptidase domain 21 208981 8747 hCG1785634.2|hCG2042897 ADAM21 ADAM metallopeptidase domain 21 180903 53616 hCG17212.4 ADAM22 ADAM metallopeptidase domain 22 177272 8745 hCG1811623.1 ADAM23 ADAM metallopeptidase domain 23 102384 10863 hCG1818505.1 ADAM28 ADAM metallopeptidase domain 28 119968 11086 hCG1786734.2 ADAM29 ADAM metallopeptidase domain 29 205542 11085 hCG1997196.1 ADAM30 ADAM metallopeptidase domain 30 148417 80332 hCG39255.4 ADAM33 ADAM metallopeptidase domain 33 140492 8756 hCG1789002.2 ADAM7 ADAM metallopeptidase domain 7 122603 101 hCG1816947.1 ADAM8 ADAM metallopeptidase domain 8 183965 8754 hCG1996391 ADAM9 ADAM metallopeptidase domain 9 (meltrin gamma) 129974 27299 hCG15447.3 ADAMDEC1 ADAM-like,
  • Immune-Checkpoint Blockade Therapy in Lymphoma

    Immune-Checkpoint Blockade Therapy in Lymphoma

    International Journal of Molecular Sciences Review Immune-Checkpoint Blockade Therapy in Lymphoma Ayumi Kuzume 1,2, SungGi Chi 1 , Nobuhiko Yamauchi 1 and Yosuke Minami 1,* 1 Department of Hematology, National Cancer Center Hospital East, Kashiwa 277–8577, Japan; [email protected] (A.K.); [email protected] (S.C.); [email protected] (N.Y.) 2 Department of Hematology, Kameda Medical Center, Kamogawa 296–8602, Japan * Correspondence: [email protected]; Tel.: +81-4-7133-1111; Fax: +81-7133-6502 Received: 11 June 2020; Accepted: 28 July 2020; Published: 30 July 2020 Abstract: Tumor cells use immune-checkpoint pathways to evade the host immune system and suppress immune cell function. These cells express programmed cell-death protein 1 ligand 1 (PD-L1)/PD-L2, which bind to the programmed cell-death protein 1 (PD-1) present on cytotoxic T cells, trigger inhibitory signaling, and reduce cytotoxicity and T-cell exhaustion. Immune-checkpoint blockade can inhibit this signal and may serve as an effective therapeutic strategy in patients with solid tumors. Several trials have been conducted on immune-checkpoint inhibitor therapy in patients with malignant lymphoma and their efficacy has been reported. For example, in Hodgkin lymphoma, immune-checkpoint blockade has resulted in response rates of 65% to 75%. However, in non-Hodgkin lymphoma, the response rate to immune-checkpoint blockade was lower. In this review, we evaluate the biology of immune-checkpoint inhibition and the current data on its efficacy in malignant lymphoma, and identify the cases in which the treatment was more effective.
  • Differential Gene Expression in Oligodendrocyte Progenitor Cells, Oligodendrocytes and Type II Astrocytes

    Differential Gene Expression in Oligodendrocyte Progenitor Cells, Oligodendrocytes and Type II Astrocytes

    Tohoku J. Exp. Med., 2011,Differential 223, 161-176 Gene Expression in OPCs, Oligodendrocytes and Type II Astrocytes 161 Differential Gene Expression in Oligodendrocyte Progenitor Cells, Oligodendrocytes and Type II Astrocytes Jian-Guo Hu,1,2,* Yan-Xia Wang,3,* Jian-Sheng Zhou,2 Chang-Jie Chen,4 Feng-Chao Wang,1 Xing-Wu Li1 and He-Zuo Lü1,2 1Department of Clinical Laboratory Science, The First Affiliated Hospital of Bengbu Medical College, Bengbu, P.R. China 2Anhui Key Laboratory of Tissue Transplantation, Bengbu Medical College, Bengbu, P.R. China 3Department of Neurobiology, Shanghai Jiaotong University School of Medicine, Shanghai, P.R. China 4Department of Laboratory Medicine, Bengbu Medical College, Bengbu, P.R. China Oligodendrocyte precursor cells (OPCs) are bipotential progenitor cells that can differentiate into myelin-forming oligodendrocytes or functionally undetermined type II astrocytes. Transplantation of OPCs is an attractive therapy for demyelinating diseases. However, due to their bipotential differentiation potential, the majority of OPCs differentiate into astrocytes at transplanted sites. It is therefore important to understand the molecular mechanisms that regulate the transition from OPCs to oligodendrocytes or astrocytes. In this study, we isolated OPCs from the spinal cords of rat embryos (16 days old) and induced them to differentiate into oligodendrocytes or type II astrocytes in the absence or presence of 10% fetal bovine serum, respectively. RNAs were extracted from each cell population and hybridized to GeneChip with 28,700 rat genes. Using the criterion of fold change > 4 in the expression level, we identified 83 genes that were up-regulated and 89 genes that were down-regulated in oligodendrocytes, and 92 genes that were up-regulated and 86 that were down-regulated in type II astrocytes compared with OPCs.
  • Human Lectins, Their Carbohydrate Affinities and Where to Find Them

    Human Lectins, Their Carbohydrate Affinities and Where to Find Them

    biomolecules Review Human Lectins, Their Carbohydrate Affinities and Where to Review HumanFind Them Lectins, Their Carbohydrate Affinities and Where to FindCláudia ThemD. Raposo 1,*, André B. Canelas 2 and M. Teresa Barros 1 1, 2 1 Cláudia D. Raposo * , Andr1 é LAQVB. Canelas‐Requimte,and Department M. Teresa of Chemistry, Barros NOVA School of Science and Technology, Universidade NOVA de Lisboa, 2829‐516 Caparica, Portugal; [email protected] 12 GlanbiaLAQV-Requimte,‐AgriChemWhey, Department Lisheen of Chemistry, Mine, Killoran, NOVA Moyne, School E41 of ScienceR622 Co. and Tipperary, Technology, Ireland; canelas‐ [email protected] NOVA de Lisboa, 2829-516 Caparica, Portugal; [email protected] 2* Correspondence:Glanbia-AgriChemWhey, [email protected]; Lisheen Mine, Tel.: Killoran, +351‐212948550 Moyne, E41 R622 Tipperary, Ireland; [email protected] * Correspondence: [email protected]; Tel.: +351-212948550 Abstract: Lectins are a class of proteins responsible for several biological roles such as cell‐cell in‐ Abstract:teractions,Lectins signaling are pathways, a class of and proteins several responsible innate immune for several responses biological against roles pathogens. such as Since cell-cell lec‐ interactions,tins are able signalingto bind to pathways, carbohydrates, and several they can innate be a immuneviable target responses for targeted against drug pathogens. delivery Since sys‐ lectinstems. In are fact, able several to bind lectins to carbohydrates, were approved they by canFood be and a viable Drug targetAdministration for targeted for drugthat purpose. delivery systems.Information In fact, about several specific lectins carbohydrate were approved recognition by Food by andlectin Drug receptors Administration was gathered for that herein, purpose. plus Informationthe specific organs about specific where those carbohydrate lectins can recognition be found by within lectin the receptors human was body.
  • Targeting Costimulatory Molecules in Autoimmune Disease

    Targeting Costimulatory Molecules in Autoimmune Disease

    Targeting costimulatory molecules in autoimmune disease Natalie M. Edner1, Gianluca Carlesso2, James S. Rush3 and Lucy S.K. Walker1 1Institute of Immunity & Transplantation, Division of Infection & Immunity, University College London, Royal Free Campus, London, UK NW3 2PF 2Early Oncology Discovery, Early Oncology R&D, AstraZeneca, Gaithersburg, MD, USA 3Autoimmunity, Transplantation and Inflammation Disease Area, Novartis Institutes for Biomedical Research, Basel, Switzerland *Correspondence: Professor Lucy S.K. Walker. Institute of Immunity & Transplantation, Division of Infection & Immunity, University College London, Royal Free Campus, London, UK NW3 2PF. Tel: +44 (0)20 7794 0500 ext 22468. Email: [email protected]. 1 Abstract Therapeutic targeting of immune checkpoints has garnered significant attention in the area of cancer immunotherapy, and efforts have focused in particular on the CD28 family members CTLA-4 and PD-1. In autoimmunity, these same pathways can be targeted to opposite effect, to curb the over- exuberant immune response. The CTLA-4 checkpoint serves as an exemplar, whereby CTLA-4 activity is blocked by antibodies in cancer immunotherapy and augmented by the provision of soluble CTLA-4 in autoimmunity. Here we review the targeting of costimulatory molecules in autoimmune disease, focusing in particular on the CD28 family and TNFR family members. We present the state-of-the-art in costimulatory blockade approaches, including rational combinations of immune inhibitory agents, and discuss the future opportunities and challenges in this field. 2 The risk of autoimmune disease is an inescapable consequence of the manner in which the adaptive immune system operates. To ensure effective immunity against a diverse array of unknown pathogens, antigen recognition systems based on random gene rearrangement and mutagenesis have evolved to anticipate the antigenic universe.
  • Wrap.Warwick.Ac.Uk/91754

    Wrap.Warwick.Ac.Uk/91754

    Original citation: Hu, Jiamiao and Christian, Mark. (2017) Hormonal factors in the control of the browning of white adipose tissue. Hormone Molecular Biology and Clinical Investigation. Permanent WRAP URL: http://wrap.warwick.ac.uk/91754 Copyright and reuse: The Warwick Research Archive Portal (WRAP) makes this work by researchers of the University of Warwick available open access under the following conditions. Copyright © and all moral rights to the version of the paper presented here belong to the individual author(s) and/or other copyright owners. To the extent reasonable and practicable the material made available in WRAP has been checked for eligibility before being made available. Copies of full items can be used for personal research or study, educational, or not-for-profit purposes without prior permission or charge. Provided that the authors, title and full bibliographic details are credited, a hyperlink and/or URL is given for the original metadata page and the content is not changed in any way. Publisher’s statement: “The final publication is available at www.degruyter.com ” http://dx.doi.org/10.1515/hmbci-2017-0017 A note on versions: The version presented here may differ from the published version or, version of record, if you wish to cite this item you are advised to consult the publisher’s version. Please see the ‘permanent WRAP URL’ above for details on accessing the published version and note that access may require a subscription. For more information, please contact the WRAP Team at: [email protected] warwick.ac.uk/lib-publications DE GRUYTER Hormone Molecular Biology and Clinical Investigation.
  • The Indoleamine 2,3 Dioxygenase Pathway Drives Intratumoral B Cell

    The Indoleamine 2,3 Dioxygenase Pathway Drives Intratumoral B Cell

    bioRxiv preprint doi: https://doi.org/10.1101/2021.08.25.456776; this version posted August 27, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission. The indoleamine 2,3 dioxygenase pathway drives intratumoral B cell maintenance. by Burles A. Johnson III1,2,3, Adam K. Aragaki2, Donna M. Williams3, Ophelia Rogers3, Jack Mountain2, Li Luo3, Wenhao Zhang3, Lingling Xian3, Mingxiao Feng2, Lionel Chia3, Dominic Dordai4, Noah M. Hahn1,2, Stephen Desiderio4, Theodore S. Johnson5, David J. McConkey2, and Linda M.S. Resar1,3,6. 1Department of Oncology, Johns Hopkins University School of Medicine, Baltimore, MD 21205 2Johns Hopkins Greenberg Bladder Cancer Institute, Johns Hopkins University School of Medicine, 600 North Wolfe Street, Park 219, Baltimore, MD 21287 3Division of Hematology, Department of Medicine, Johns Hopkins University School of Medicine, 720 Rutland Avenue, Ross Research Building, Room 1025, Baltimore, MD 21205 4Institute for Basic Biomedical Sciences, Johns Hopkins University School of Medicine, Baltimore, MD 21205 5Georgia Cancer Center and Department of Pediatrics, Augusta University, 1120 15th Street, Augusta, GA 30912 6Department of Pathology and Institute for Cellular Engineering, Johns Hopkins University School of Medicine, Baltimore, MD 21205 Abstract: 219 words; Manuscript Text: 4929 words Correspondence: [email protected] or [email protected] Abbreviations: IDO1, indoleamine 2,3 dioxygenase-1; Bregs, regulatory B cells, Tregs, regulatory T cells; LLC, Lewis Lung Carcinoma; PD-1/L, programmed cell death protein-1/ligand; APCs, antigen presenting cells; MDSCs, myeloid derived suppressor cells; IL, interleukin. bioRxiv preprint doi: https://doi.org/10.1101/2021.08.25.456776; this version posted August 27, 2021.
  • Suppressive Myeloid Cells Are a Hallmark of Severe COVID-19

    Suppressive Myeloid Cells Are a Hallmark of Severe COVID-19

    medRxiv preprint doi: https://doi.org/10.1101/2020.06.03.20119818; this version posted June 5, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license . 1 Suppressive myeloid cells are a hallmark of 2 severe COVID-19 3 Jonas Schulte-Schrepping1*, Nico Reusch1*, Daniela Paclik2*, Kevin Baßler1*, Stephan 4 Schlickeiser3*, Bowen Zhang4*, Benjamin Krämer5*, Tobias Krammer6*, Sophia Brumhard7*, 5 Lorenzo Bonaguro1*, Elena De Domenico8*, Daniel Wendisch7*, Martin Grasshoff4, Theodore S. 6 Kapellos1, Michael Beckstette4, Tal Pecht1, Adem Saglam8, Oliver Dietrich6, Henrik E. Mei9, Axel 7 R. Schulz9, Claudia Conrad7, Désirée Kunkel10, Ehsan Vafadarnejad6, Cheng-Jian Xu4,11, Arik 8 Horne1, Miriam Herbert1, Anna Drews8, Charlotte Thibeault7, Moritz Pfeiffer7, Stefan 9 Hippenstiel7,12, Andreas Hocke7,12, Holger Müller-Redetzky7, Katrin-Moira Heim7, Felix Machleidt7, 10 Alexander Uhrig7, Laure Bousquillon de Jarcy7, Linda Jürgens7, Miriam Stegemann7, Christoph 11 R. Glösenkamp7, Hans-Dieter Volk2,3,13, Christine Goffinet14,15, Jan Raabe5, Kim Melanie Kaiser5, 12 Michael To Vinh5, Gereon Rieke5, Christian Meisel14, Thomas Ulas8, Matthias Becker8, Robert 13 Geffers16, Martin Witzenrath7,12, Christian Drosten14,19, Norbert Suttorp7,12, Christof von Kalle17, 14 Florian Kurth7,18, Kristian Händler8, Joachim L. Schultze1,8,#,$, Anna C Aschenbrenner20,#, Yang 15 Li4,#,